Spanish healthcare firm Grifols (GRLS.MC), which is in the throes of a $4 billion takeover of U.S. peer Talecris (TLCR.O), posted a 13.7 percent decline in 2010 net profit due to higher financing costs. Net profit was 127.7 million euros ($175.7 million), in line with a Reuters poll forecast. [ID:nLDE71F1S1] Grifols' purchase of Talecris would create the world's third-largest maker of medicines derived from intravenous immune globulin (IVIG), albumin and other products from blood plasma.
Source
